NASDAQ: CRBP
Corbus Pharmaceuticals Holdings Inc Stock

$8.28-0.46 (-5.26%)
Updated Jun 17, 2025
CRBP Price
$8.28
Fair Value Price
$1.28
Market Cap
$101.32M
52 Week Low
$4.64
52 Week High
$61.90
P/E
-1.97x
P/B
0.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$50.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$50M
Beta
1.58
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CRBP Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CRBP's potential to beat the market

FStrong Sell
  • Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More

Zen Rating Component Grades

F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
CRBP
Ranked
#386 of 464

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important CRBP news, forecast changes, insider trades & much more!

CRBP News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CRBP ($8.28) is overvalued by 547.46% relative to our estimate of its Fair Value price of $1.28 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRBP ($8.28) is not significantly undervalued (547.46%) relative to our estimate of its Fair Value price of $1.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRBP due diligence checks available for Premium users.

Valuation

CRBP fair value

Fair Value of CRBP stock based on Discounted Cash Flow (DCF)

Price
$8.28
Fair Value
$1.28
Overvalued by
547.46%
CRBP ($8.28) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRBP ($8.28) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CRBP price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.97x
Industry
-111.62x
Market
26.81x

CRBP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.8x
Industry
4.49x
CRBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CRBP's financial health

Profit margin

Revenue
$0.0
Net Income
-$17.0M
Profit Margin
0%
CRBP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$139.9M
Liabilities
$12.8M
Debt to equity
0.1
CRBP's short-term assets ($137.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRBP's short-term assets ($137.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRBP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$16.4M
Investing
$18.1M
Financing
$0.0
CRBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CRBP vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CRBPF$101.32M-5.26%-1.97x0.80x
CTNMF$101.68M-8.39%-1.98x0.55x
NTHIC$100.84M-6.69%N/A-10.48x
SAVAF$100.00M+0.98%-1.35x0.78x
ACHVF$103.36M-3.87%-2.22x10.06x

Corbus Pharmaceuticals Holdings Stock FAQ

What is Corbus Pharmaceuticals Holdings's quote symbol?

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings trades on the NASDAQ under the ticker symbol CRBP. Corbus Pharmaceuticals Holdings stock quotes can also be displayed as NASDAQ: CRBP.

If you're new to stock investing, here's how to buy Corbus Pharmaceuticals Holdings stock.

What is the 52 week high and low for Corbus Pharmaceuticals Holdings (NASDAQ: CRBP)?

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's 52-week high was $61.90, and its 52-week low was $4.64. It is currently -86.62% from its 52-week high and 78.45% from its 52-week low.

How much is Corbus Pharmaceuticals Holdings stock worth today?

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings currently has 12,236,767 outstanding shares. With Corbus Pharmaceuticals Holdings stock trading at $8.28 per share, the total value of Corbus Pharmaceuticals Holdings stock (market capitalization) is $101.32M.

Corbus Pharmaceuticals Holdings stock was originally listed at a price of $90.00 in Nov 11, 2014. If you had invested in Corbus Pharmaceuticals Holdings stock at $90.00, your return over the last 10 years would have been -90.8%, for an annualized return of -21.23% (not including any dividends or dividend reinvestments).

How much is Corbus Pharmaceuticals Holdings's stock price per share?

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings stock price per share is $8.28 today (as of Jun 17, 2025).

What is Corbus Pharmaceuticals Holdings's Market Cap?

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's market cap is $101.32M, as of Jun 18, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Corbus Pharmaceuticals Holdings's market cap is calculated by multiplying CRBP's current stock price of $8.28 by CRBP's total outstanding shares of 12,236,767.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.